Compare Mercadolibre Inc (MELI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Novavax Inc — how do they compare? Mercadolibre Inc trades at $1,840.01 (market cap $98.35B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Mercadolibre Inc is far larger — about 75.1× Novavax Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| MELI | NVAX | |
|---|---|---|
Market Cap | $98.35B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $11.19 |
52-Week Low | $1.55K | $6.22 |
Enterprise Value | $106.00B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,828.29, up 0.22% with strong technical bullish signals from moving averages. The company demonstrates exceptional revenue growth, reaching $28.89 billion in 2025, though recent earnings misses and margin pressures from strategic investments have tempered investor enthusiasm. Analyst consensus remains strongly bullish with a $2,150 price target, representing 17.6% upside potential from current levels.
MELI's growth-first strategy is driving market share gains but sacrificing near-term profitability. The stock presents a compelling opportunity for long-term investors willing to tolerate margin volatility, though execution risks and competitive pressures in Latin American e-commerce warrant careful monitoring. Current valuation at 52.77 P/E reflects premium pricing for high-growth expectations.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
